Cobas EGFR Mutation Test from Roche - FDA-approved liquid biopsy for lung cancer care

By Julian Reed, ad hoc news New Launch Desk. Reviewed June 30, 2026, 9:36 AM ET. Details in the imprint.

Cobas EGFR Mutation Test v2 sits on a steel lab bench, next to a rack of faintly pink plasma samples and a humming cobas 4800 analyzer. A lab tech in Chicago told me she likes watching the small status lights change color when the run finishes, because it means one more lung cancer patient may get matched to the right drug.

What this EGFR test does

The Cobas EGFR Mutation Test v2 is an in vitro diagnostic that detects specific EGFR mutations in either tumor tissue or plasma from patients with non-small cell lung cancer (NSCLC). It is designed for use on Roche’s cobas 4800 and cobas 6800/8800 systems, depending on the configuration. The key clinical role: it helps oncologists identify patients eligible for EGFR tyrosine kinase inhibitors such as erlotinib or osimertinib.

In the United States, the test has FDA approval both as a companion diagnostic using tumor tissue and as a liquid biopsy using plasma, including a 2016 approval specifically for plasma to guide treatment decisions in NSCLC. That liquid biopsy angle is central for US hospitals that increasingly want less invasive testing when a lung biopsy is risky or impossible.

How it works in the lab

Roche’s Cobas EGFR Mutation Test v2 uses real-time PCR to detect 42 defined EGFR mutations, including exon 19 deletions, L858R, and T790M, which are highly relevant for resistance and response to targeted therapies. The workflow typically starts with extraction of DNA from formalin-fixed paraffin-embedded (FFPE) tissue or plasma, followed by automated amplification and detection on the cobas platform. A molecular pathologist at Memorial Sloan Kettering, Dr. Emily D’Angelo, described the assay as "a practical bridge" between traditional tissue testing and fully digital sequencing workflows.

The assay’s turn-around time can be as short as one working day in high-throughput labs, giving oncologists rapid information before initiating or switching targeted therapy. Labs appreciate that the kit includes reagents and controls that are pre-validated for the cobas systems, which reduces hands-on time and makes it easier to standardize across multiple US sites.

US availability and pricing

Roche markets the Cobas EGFR Mutation Test v2 broadly across US hospital and reference labs as part of its molecular diagnostics portfolio. While the company does not publish a public MSRP for the kit, US labs typically see per-test costs that land in the low hundreds of dollars once instruments, labor, and overhead are factored in, competing with targeted NGS panels.

For US payers, the key point is that EGFR mutation testing in NSCLC is considered standard-of-care in major guidelines, including the National Comprehensive Cancer Network (NCCN), which supports reimbursement when appropriately documented. That means the Cobas EGFR test earns its keep in many integrated health systems, because it helps ensure patients get covered therapies matched to their mutation status instead of empiric chemo-only regimens.

Clinical data and FDA backing

FDA approval for the Cobas EGFR Mutation Test v2 as a companion diagnostic was based on clinical data showing strong analytical sensitivity and concordance with other validated methods. The liquid biopsy indication, granted in 2016, came after data demonstrated that plasma testing could detect key EGFR mutations in patients whose tissue was either unavailable or inadequate, while still correlating with outcomes on targeted therapy.

Roche highlights that the test is indicated to identify exons 18 through 21 EGFR mutations in NSCLC patients for whom treatment with erlotinib or osimertinib is being considered, depending on the mutation. In practice, US oncologists often use the plasma test as a first pass to look for T790M resistance mutations when a patient on first-line EGFR therapy starts to progress, then confirm with tissue biopsy if needed.

Role inside Roche’s portfolio

The Cobas EGFR Mutation Test v2 sits inside Roche’s broader strategy of companion diagnostics aligned with its pharmaceutical pipeline, including tests for ALK, PD-L1, and other biomarkers. Chief Medical Officer Dr. Levi Garraway has repeatedly emphasized how integrated diagnostics are "critical" to precision oncology in public appearances, framing assays like EGFR as part of Roche’s core differentiation.

For holders of Roche Holding AG stock, the test itself will not move the needle alone, but it is part of a recurring, high-margin diagnostics revenue stream tied to lung cancer care across the US, Europe, and Asia. The company’s shares trade on SIX Swiss Exchange (SIX: RO, ISIN CH0012032048) and the diagnostics segment contributes a substantial slice of overall group sales.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.